Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 564 record(s)

Req # A-2022-001054

Adverse Drug Reaction (ADR). Report number: E2B_04238483.

Organization: Health Canada

67 page(s)
February 2023

Req # A-2022-001064

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-105095-605.

Organization: Health Canada

7 page(s)
February 2023

Req # A-2022-001070

Adverse Drug Reactions (ADRs) for Alendronic Acid. Report numbers: 000716510, E2B 02034338, E2B 02039383, E2B 02043606, E2B 02048160, E2B 02052077, E2B 02058874, 000720911, E2B 01781006.

Organization: Health Canada

111 page(s)
February 2023

Req # A-2022-001072

Adverse Drug Reaction (ADR). Report number: E2B_05322214.

Organization: Health Canada

605 page(s)
February 2023

Req # A-2022-001080

Adverse Drug Reaction (ADR) for JINARC. Report number: 001008538. ADRs for REXULTI. Report numbers: 001006210, E2B_05645875, E2B_05646027, E2B_05702141. ADR for ARIPIPRAZOLE. Report number: 001006264. ADRs for ABILIFY. Report numbers: E2B_05660398, E2B_05660400.

Organization: Health Canada

97 page(s)
February 2023

Req # A-2022-001081

Adverse Drug Reactions (ADRs) for CELEXA. Report numbers: 00979116, 00978656, E2B_05023024, 00982655, 00978530. ADRs for CLOPIXOL. Report numbers: E2B_04897492, E2B_04773927, E2B_05008311. ADR for TRINTELLIX. Report number: 00970777.

Organization: Health Canada

150 page(s)
February 2023

Req # A-2022-001086

Adverse Drug Reactions (ADRs) for ABILIFY MAINTENA. Report numbers: E2B_05664957, E2B_05664982, E2B_05665009, E2B_05665010, E2B_05651560, E2B_05662861, E2B_05662992, E2B_05662994.

Organization: Health Canada

213 page(s)
February 2023

Req # A-2022-001089

Adverse Drug Reactions (ADRs). Report numbers: E2B_05605266, E2B_05029637, 001005578.

Organization: Health Canada

94 page(s)
February 2023

Req # A-2022-001090

Adverse Drug Reaction (ADR). Report number: E2B_05211145.

Organization: Health Canada

9 page(s)
February 2023

Req # A-2022-001095

Adverse Drug Reactions (ADRs) for ALENDRONIC ACID. Report numbers: E2B_01775951, E2B_01780967, E2B_02142492, E2B_02272688, E2B_02272700, 000715927, E2B_01738850, E2B_02094125.

Organization: Health Canada

352 page(s)
February 2023
Date modified: